General Atlantic’s Ginkgo Bioworks DNA Stock Holding History

General Atlantic’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-807,997	Closed	-$60.1M	–	30
2023 Q2	$60.1M	Hold	807,997	–	–	0.95%	15
2023 Q1	$43M	Hold	807,997	–	–	0.5%	20
2022 Q4	$54.6M	Hold	807,997	–	–	0.72%	17
2022 Q3	$101M	Sell	807,997 -927,896	-53%	-$111M	1.19%	13
2022 Q2	$165M	Sell	1,735,893 -534,377	-24%	-$65.2M	2.16%	10
2022 Q1	$366M	Sell	2,270,270 -518,887	-19%	-$101M	3.35%	9
2021 Q4	$927M	Sell	2,789,157 -83,014	-3%	-$39.4M	7.15%	6
2021 Q3	$1.33B	Buy	+2,872,171	New	+$1.4B	7.8%	5

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

General Atlantic's DNA Position: Q3 2023 in Review

General Atlantic sold out of Ginkgo Bioworks (DNA) in Q3 2023, closing a stake of 807,997 shares — an estimated $60.1M sold.

General Atlantic first reported a position in DNA in Q3 2021 and held it in 8 quarters. The position peaked at $1.33B in Q3 2021. 349 funds tracked by Wall St. Rank hold DNA as of Q3 2023.

General Atlantic reported no remaining Ginkgo Bioworks position as of Q3 2023 after selling out during the quarter.
General Atlantic sold 807,997 Ginkgo Bioworks shares in Q3 2023, an estimated $60.1M.
General Atlantic first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 8 quarters.
General Atlantic's Ginkgo Bioworks position peaked at $1.33B in Q3 2021.
349 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2023.

Based on General Atlantic's 13F filing for Q3 2023, filed 14 Nov 2023.